Research programme: bacterial and fungal vaccines - NovaDigm Therapeutics
Alternative Names: Candida vaccines - NovaDigm Therapeutics; Meticillin-resistant Staphylococcus aureus vaccine - NovaDigm TherapeuticsLatest Information Update: 16 Jul 2016
At a glance
- Originator NovaDigm Therapeutics
- Class Bacterial vaccines; Fungal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Candidiasis; Staphylococcal infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Candidiasis in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA (Parenteral)
- 01 Dec 2008 Preclinical trials in Candidiasis in USA (Parenteral)